AU2012278921B2 - Combination therapy - Google Patents

Combination therapy Download PDF

Info

Publication number
AU2012278921B2
AU2012278921B2 AU2012278921A AU2012278921A AU2012278921B2 AU 2012278921 B2 AU2012278921 B2 AU 2012278921B2 AU 2012278921 A AU2012278921 A AU 2012278921A AU 2012278921 A AU2012278921 A AU 2012278921A AU 2012278921 B2 AU2012278921 B2 AU 2012278921B2
Authority
AU
Australia
Prior art keywords
cancer
individual
receptor
antibody
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012278921A
Other languages
English (en)
Other versions
AU2012278921A1 (en
Inventor
Julian Alexander Barden
Angus Gidley-Baird
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosceptre International Ltd
Original Assignee
Biosceptre International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011902623A external-priority patent/AU2011902623A0/en
Application filed by Biosceptre International Ltd filed Critical Biosceptre International Ltd
Priority to AU2012278921A priority Critical patent/AU2012278921B2/en
Publication of AU2012278921A1 publication Critical patent/AU2012278921A1/en
Application granted granted Critical
Publication of AU2012278921B2 publication Critical patent/AU2012278921B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012278921A 2011-07-01 2012-07-02 Combination therapy Active AU2012278921B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012278921A AU2012278921B2 (en) 2011-07-01 2012-07-02 Combination therapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2011902623 2011-07-01
AU2011902623A AU2011902623A0 (en) 2011-07-01 Combination therapy
PCT/AU2012/000795 WO2013003895A1 (en) 2011-07-01 2012-07-02 Combination therapy
AU2012278921A AU2012278921B2 (en) 2011-07-01 2012-07-02 Combination therapy

Publications (2)

Publication Number Publication Date
AU2012278921A1 AU2012278921A1 (en) 2014-01-16
AU2012278921B2 true AU2012278921B2 (en) 2016-11-10

Family

ID=47436374

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012278921A Active AU2012278921B2 (en) 2011-07-01 2012-07-02 Combination therapy

Country Status (11)

Country Link
US (3) US9566318B2 (https=)
EP (1) EP2726095B1 (https=)
JP (2) JP6305920B2 (https=)
CN (1) CN103702683B (https=)
AU (1) AU2012278921B2 (https=)
BR (1) BR112013033974A2 (https=)
CA (1) CA2840251C (https=)
ES (1) ES2689272T3 (https=)
MX (1) MX349321B (https=)
WO (1) WO2013003895A1 (https=)
ZA (1) ZA201400120B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
US8933263B2 (en) 2010-12-29 2015-01-13 Ecolab Usa Inc. Water temperature as a means of controlling kinetics of onsite generated peracids
US8846107B2 (en) 2010-12-29 2014-09-30 Ecolab Usa Inc. In situ generation of peroxycarboxylic acids at alkaline pH, and methods of use thereof
MX349321B (es) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.
US9321664B2 (en) 2011-12-20 2016-04-26 Ecolab Usa Inc. Stable percarboxylic acid compositions and uses thereof
EP3766523A1 (en) 2014-12-18 2021-01-20 Ecolab USA Inc. Generation of peroxyformic acid through polyhydric alcohol formate
EP3232781A4 (en) 2014-12-18 2018-08-22 Ecolab USA Inc. Methods for forming peroxyformic acid and uses thereof
US11040902B2 (en) 2014-12-18 2021-06-22 Ecolab Usa Inc. Use of percarboxylic acids for scale prevention in treatment systems
US12121539B2 (en) 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
MX2019004410A (es) * 2016-10-21 2019-09-26 Biosceptre Uk Ltd Particulas citotoxicas.
EP3841059A1 (en) 2018-08-22 2021-06-30 Ecolab USA Inc. Hydrogen peroxide and peracid stabilization with molecules based on a pyridine carboxylic acid at c-3, -4 or -5
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
CN114173811A (zh) * 2019-07-26 2022-03-11 生物权威(澳大利亚)有限责任公司 P2x7受体靶向治疗

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033233A1 (en) * 2007-09-14 2009-03-19 Biosceptre International Limited Novel p2x7 epitopes
WO2011075789A1 (en) * 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
WO2012031333A1 (en) * 2010-09-10 2012-03-15 Biosceptre International Limited Companion animal treatments

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
AU2566595A (en) 1994-05-27 1995-12-21 Glaxo Group Limited P-2x receptors (purinoceptor family)
WO1997006256A2 (en) 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
JP2001521372A (ja) 1996-04-30 2001-11-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ヒトＰ２ｘ４レセプタースプライス−変異体
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
EP1086223B1 (en) 1998-06-01 2009-07-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
DE19829473C2 (de) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
NL1012452C2 (nl) 1999-06-28 2001-01-02 Univ Delft Tech Werkwijze voor de bereiding van eiwit-agglomeraten, eiwit-agglomeraten, een levensmiddel en een farmaceutisch preparaat die deze bevatten alsmede een inrichting voor het bereiden van eiwit-agglomeraten.
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
CN100497386C (zh) 2001-09-03 2009-06-10 因特里特有限公司 非功能性p2x7受体的抗体及其应用
EP1469072B1 (en) 2003-04-17 2007-08-29 Affectis Pharmaceuticals AG Means and methods for diagnosing and treating affective disorders
DE602005017743D1 (de) * 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
US7858323B2 (en) * 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
GB0419295D0 (en) * 2004-08-31 2004-09-29 Genomica Sau Methods and compositions to prevent neuronal degeneration
CA2607541A1 (en) 2005-05-05 2006-12-28 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
EP1929305A2 (en) 2005-08-31 2008-06-11 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2008043146A1 (en) 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
JP2010505426A (ja) 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
KR20170097234A (ko) * 2008-12-10 2017-08-25 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 유방암 재발 예방용 백신
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
US8828944B2 (en) * 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
MX349321B (es) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033233A1 (en) * 2007-09-14 2009-03-19 Biosceptre International Limited Novel p2x7 epitopes
WO2011075789A1 (en) * 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
WO2012031333A1 (en) * 2010-09-10 2012-03-15 Biosceptre International Limited Companion animal treatments

Also Published As

Publication number Publication date
ES2689272T3 (es) 2018-11-13
BR112013033974A2 (pt) 2017-02-14
AU2012278921A1 (en) 2014-01-16
ZA201400120B (en) 2015-09-30
EP2726095A4 (en) 2015-01-07
CA2840251A1 (en) 2013-01-10
JP2018087249A (ja) 2018-06-07
US10543262B2 (en) 2020-01-28
US20190224290A1 (en) 2019-07-25
CN103702683A (zh) 2014-04-02
US20150004179A1 (en) 2015-01-01
US20170157229A1 (en) 2017-06-08
JP2014520759A (ja) 2014-08-25
CA2840251C (en) 2023-09-12
MX349321B (es) 2017-07-21
EP2726095B1 (en) 2018-06-06
MX2014000199A (es) 2014-06-11
CN103702683B (zh) 2017-07-04
US10245308B2 (en) 2019-04-02
JP6490270B2 (ja) 2019-03-27
EP2726095A1 (en) 2014-05-07
JP6305920B2 (ja) 2018-04-04
WO2013003895A1 (en) 2013-01-10
US9566318B2 (en) 2017-02-14

Similar Documents

Publication Publication Date Title
US10543262B2 (en) Combination therapy utilizing P2X7 peptides
ES2904911T3 (es) Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
US9428587B2 (en) Antibodies to non-functional oligomeric P2X7 receptors and methods of use thereof
US10232025B2 (en) Method for minimising progression of cancer in companion animals
US20220251187A1 (en) P2x7 receptor targeted therapy
HK1195258A (en) Combination therapy
HK1195258B (en) Combination therapy
CN103298487B (zh) 陪伴动物治疗
HK1188401A (en) Companion animal treatments

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)